General information
Immunic AG
Lochhamer Schlag 21
82166 Gräfelfing, Bavaria
Germany
Contact person: Jessica Breu, Head of Investor Relations and Communications
Company main phone: +49 (89) 2080 477 00
Website: https://imux.com/
Year founded: | 2016
|
Source of foundation: | Subsidiary |
Name of foundation source: | Immunic, Inc., USA |
Corporate description / mission:
Immunic AG is focused on the development of immune modulators to block TH17- and TH1-mediated immune and autoimmune responses. The company develops immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn’s disease, and psoriasis. The company’s two development programs include orally available, small molecule inhibitors of DHODH (IMU-838 program) and RORγt (IMU-366 program) relevant to diseases such as Ulcerative Colitis, Crohn’s disease and psoriasis.
State of ownership: Subsidiary
Headquarters: No
Categorization
Sector: |
- Biotechnology - Therapeutics and Diagnostics
|
Subsector: |
- Immunotherapy
- Small molecules
|
Primary therapeutic areas: |
- Digestive system / gastroenterology
- Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
- Diseases of the nervous system / neurology
- Skin and subcutaneous tissue / dermatology
- Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
|
Customer segments: |
- Hospitals
- Large biotech & big pharma
|
Summary Products / Services / Technologies
Description of products:
DHODH (IMU-838 program) and RORγt (IMU-366 program)